{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:20:25Z","timestamp":1784694025601,"version":"3.55.0"},"reference-count":120,"publisher":"Bentham Science Publishers Ltd.","issue":"29","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec><jats:title>Abstract:<\/jats:title><jats:p>Psoriasis is defined as a chronic autoimmune disorder of the skin in which abnormal proliferation and differentiation of keratinocytes are blamed as the central culprit of disease etiopathogenesis. A complex interplay between environmental factors and genetic risk factors has been suggested to trigger the disease. However, epigenetic regulation appears to connect external stimuli and genetic abnormalities in the development of psoriasis. The discordance in the prevalence of psoriasis between monozygotic twins and environmental factors that contribute to its onset have caused a paradigm shift regarding the mechanisms underlying the pathogenesis of this disease. Epigenetic dysregulation may be involved in aberrancies of keratinocyte differentiation, T-cell activation, and other plausible cells, leading to the initiation and perpetuation of psoriasis. Epigenetics is characterized by heritable alterations in the transcription of genes without nucleotide change and is commonly considered at three levels, i.e., DNA methylation, histone modifications, and microRNAs. To date, scientific evidence has indicated abnormal DNA methylation, histone modifications, and non-coding RNA transcription in psoriatic patients. In order to reverse aberrant epigenetic changes in psoriasis patients, several compounds and drugs (epi-drugs) have been developed to affect the major enzymes involved in the methylation of DNA, or the acetylation of histones, which aim to correct the aberrant methylation and acetylation patterns. A number of clinical trials have suggested the therapeutic potential of such drugs in the treatment of psoriasis. In the present review, we attempt to clarify recent findings with respect to epigenetic irregularities in psoriasis and discuss future challenges.<\/jats:p><\/jats:sec><jats:sec><jats:title>Abstract:<\/jats:title><jats:p>Psoriasis is defined as a chronic autoimmune disorder of the skin in which abnormal proliferation and differentiation of keratinocytes are blamed as the central culprit of disease etiopathogenesis. A complex interplay between environmental factors and genetic risk factors has been suggested to trigger the disease. However, epigenetic regulation appears to connect external stimuli and genetic abnormalities in the development of psoriasis. The discordance in the prevalence of psoriasis between monozygotic twins and environmental factors that contribute to its onset have caused a paradigm shift regarding the mechanisms underlying the pathogenesis of this disease. Epigenetic dysregulation may be involved in aberrancies of keratinocyte differentiation, T-cell activation, and other plausible cells, leading to the initiation and perpetuation of psoriasis. Epigenetics is characterized by heritable alterations in the transcription of genes without nucleotide change and is commonly considered at three levels, i.e., DNA methylation, histone modifications, and microRNAs. To date, scientific evidence has indicated abnormal DNA methylation, histone modifications, and non-coding RNA transcription in psoriatic patients. In order to reverse aberrant epigenetic changes in psoriasis patients, several compounds and drugs (epi-drugs) have been developed to affect the major enzymes involved in the methylation of DNA, or the acetylation of histones, which aim to correct the aberrant methylation and acetylation patterns. A number of clinical trials have suggested the therapeutic potential of such drugs in the treatment of psoriasis. In the present review, we attempt to clarify recent findings with respect to epigenetic irregularities in psoriasis and discuss future challenges.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867330666230503143824","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T04:40:32Z","timestamp":1683175232000},"page":"4621-4639","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Epigenetic Contribution to the Pathogenesis of Psoriasis: Recent Advances"],"prefix":"10.2174","volume":"31","author":[{"given":"Saeed","family":"Aslani","sequence":"first","affiliation":[{"name":"Department of Molecular and Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC 3800, Australia"},{"name":"Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohamad Javad","family":"Mirarefin","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Zarredar","sequence":"additional","affiliation":[{"name":"Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Asadi","sequence":"additional","affiliation":[{"name":"Department of Basic Oncology, Institute of Health Sciences , Ege University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Javan","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medicine, Zabol University of Medical Sciences, Zabol, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezou","family":"Khosrojerdi","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO 64110 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[{"name":"Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"School of Medicine, The University of Western Australia, Perth, Australia"},{"name":"Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1759720X19886505","DOI":"10.1177\/1759720X19886505","volume":"11","author":"Frischknecht L.","year":"2019","unstructured":"Frischknecht L.; Vecellio M.; Selmi C.; The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis. Ther Adv Musculoskeletal D 2019,11,1759720X19886505","journal-title":"Ther Adv Musculoskeletal D"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/bjd.19169","volume":"184","author":"Iskandar I.Y.K.","year":"2021","unstructured":"Iskandar I.Y.K.; Parisi R.; Griffiths C.E.M.; Ashcroft D.M.; Atlas G.P.; Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender. Br J Dermatol 2021,184(2),243-258","journal-title":"Br J Dermatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","volume":"34","author":"Chandran V.","year":"2010","unstructured":"Chandran V.; Raychaudhuri S.P.; Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010,34(3),J314-J321","journal-title":"J Autoimmun"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"e1002454","DOI":"10.1371\/journal.pgen.1002454","volume":"8","author":"Gervin K.","year":"2012","unstructured":"Gervin K.; Vigeland M.D.; Mattingsdal M.; Hammer\u00f8 M.; Nyg\u00e5rd H.; Olsen A.O.; Brandt I.; Harris J.R.; Undlien D.E.; Lyle R.; DNA methylation and gene expression changes in monozygotic twins discordant for psoriasis: Identification of epigenetically dysregulated genes. PLoS Genet 2012,8(1),e1002454","journal-title":"PLoS Genet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"778677","DOI":"10.3389\/fcell.2021.778677","volume":"9","author":"Vecellio M.","year":"2021","unstructured":"Vecellio M.; Paraboschi E.M.; Ceribelli A.; Isailovic N.; Motta F.; Cardamone G.; Robusto M.; Asselta R.; Brescianini S.; Sacrini F.; Costanzo A.; De Santis M.; Stazi M.A.; Duga S.; Selmi C.; DNA methylation signature in monozygotic twins discordant for psoriatic disease. Front Cell Dev Biol 2021,9,778677","journal-title":"Front Cell Dev Biol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.biocel.2015.05.022","volume":"67","author":"Zhao M.","year":"2015","unstructured":"Zhao M.; Wang Z.; Yung S.; Lu Q.; Epigenetic dynamics in immunity and autoimmunity. Int J Biochem Cell Biol 2015,67,65-74","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12016-009-8165-7","volume":"39","author":"Zhao S.","year":"2010","unstructured":"Zhao S.; Long H.; Lu Q.; Epigenetic perspectives in systemic lupus erythematosus: pathogenesis, biomarkers, and therapeutic potentials. Clin Rev Allergy Immunol 2010,39(1),3-9","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.molmed.2011.07.005","volume":"17","author":"Hedrich C.M.","year":"2011","unstructured":"Hedrich C.M.; Tsokos G.C.; Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends Mol Med 2011,17(12),714-724","journal-title":"Trends Mol Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1586\/1744666X.2015.994507","volume":"11","author":"Jeffries M.A.","year":"2015","unstructured":"Jeffries M.A.; Sawalha A.H.; Autoimmune disease in the epigenetic era: How has epigenetics changed our understanding of disease and how can we expect the field to evolve? Expert Rev Clin Immunol 2015,11(1),45-58","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jaut.2016.06.020","volume":"74","author":"Long H.","year":"2016","unstructured":"Long H.; Yin H.; Wang L.; Gershwin M.E.; Lu Q.; The critical role of epigenetics in systemic lupus erythematosus and autoimmunity. J Autoimmun 2016,74,118-138","journal-title":"J Autoimmun"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1002\/art.11090","volume":"48","author":"Okada S.","year":"2003","unstructured":"Okada S.; Weatherhead E.; Targoff I.N.; Wesley R.; Miller F.W.; Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003,48(8),2285-2293","journal-title":"Arthritis Rheum"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"33036","DOI":"10.1074\/jbc.M112.383273","volume":"287","author":"Tan G.","year":"2012","unstructured":"Tan G.; Niu J.; Shi Y.; Ouyang H.; Wu Z.H.; NF-\u03baB-dependent microRNA-125b up-regulation promotes cell survival by targeting p38\u03b1 upon ultraviolet radiation. J Biol Chem 2012,287(39),33036-33047","journal-title":"J Biol Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1039\/c1pp05197k","volume":"11","author":"Chen I.P.","year":"2012","unstructured":"Chen I.P.; Henning S.; Faust A.; Boukamp P.; Volkmer B.; Greinert R.; UVA-induced epigenetic regulation of P16INK4a in human epidermal keratinocytes and skin tumor derived cells. Photochem Photobiol Sci 2012,11(1),180-190","journal-title":"Photochem Photobiol Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1540-9740.2005.03716.x","volume":"4","author":"Shahrad M B.","year":"2005","unstructured":"Shahrad M B.; Shahdad E B.; John Y K.; Smoking and Psoriasis. Skinmed 2005,4(3),174-176","journal-title":"Skinmed"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1289\/ehp.1307480","volume":"122","author":"Harlid S.","year":"2014","unstructured":"Harlid S.; Xu Z.; Panduri V.; Sandler D.P.; Taylor J.A.; CpG sites associated with cigarette smoking: Analysis of epigenome-wide data from the Sister Study. Environ Health Perspect 2014,122(7),673-678","journal-title":"Environ Health Perspect"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12017-016-8422-x","volume":"19","author":"Aslani S.","year":"2017","unstructured":"Aslani S.; Jafari N.; Javan M.R.; Karami J.; Ahmadi M.; Jafarnejad M.; Epigenetic modifications and therapy in multiple sclerosis. Neuromole Med 2017,19(1),11-23","journal-title":"Neuromole Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1007\/s10067-016-3403-x","volume":"35","author":"Aslani S.","year":"2016","unstructured":"Aslani S.; Mahmoudi M.; Garshasbi M.; Jamshidi A.R.; Karami J.; Nicknam M.H.; Evaluation of DNMT1 gene expression profile and methylation of its promoter region in patients with ankylosing spondylitis. Clin Rheumatol 2016,35(11),2723-2731","journal-title":"Clin Rheumatol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/jcp.26911","volume":"234","author":"Mousavi M.J.","year":"2019","unstructured":"Mousavi M.J.; Jamshidi A.; Chopra A.; Aslani S.; Akhlaghi M.; Mahmoudi M.; Implications of the noncoding RNAs in rheumatoid arthritis pathogenesis. J Cell Physiol 2019,234(1),335-347","journal-title":"J Cell Physiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/gene.2017.17","volume":"18","author":"Karami J.","year":"2017","unstructured":"Karami J.; Mahmoudi M.; Amirzargar A.; Gharshasbi M.; Jamshidi A.; Aslani S.; Nicknam M.H.; Promoter hypermethylation of BCL11B gene correlates with downregulation of gene transcription in ankylosing spondylitis patients. Genes Immun 2017,18(3),170-175","journal-title":"Genes Immun"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.biopha.2018.02.030","volume":"100","author":"Soltanzadeh-Yamchi M.","year":"2018","unstructured":"Soltanzadeh-Yamchi M.; Shahbazi M.; Aslani S.; Mohammadnia-Afrouzi M.; MicroRNA signature of regulatory T cells in health and autoimmunity. Biomed Pharmacother 2018,100,316-323","journal-title":"Biomed Pharmacother"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.humimm.2018.01.003","volume":"79","author":"Aslani S.","year":"2018","unstructured":"Aslani S.; Sobhani S.; Gharibdoost F.; Jamshidi A.; Mahmoudi M.; Epigenetics and pathogenesis of systemic sclerosis; the ins and outs. Hum Immunol 2018,79(3),178-187","journal-title":"Hum Immunol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.biopha.2016.12.072","volume":"87","author":"Ahmadi M.","year":"2017","unstructured":"Ahmadi M.; Gharibi T.; Dolati S.; Rostamzadeh D.; Aslani S.; Baradaran B.; Younesi V.; Yousefi M.; Epigenetic modifications and epigenetic based medication implementations of autoimmune diseases. Biomed Pharmacother 2017,87,596-608","journal-title":"Biomed Pharmacother"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"12309","DOI":"10.1002\/jcp.28020","volume":"234","author":"Fathollahi A.","year":"2019","unstructured":"Fathollahi A.; Aslani S.; Jamshidi A.; Mahmoudi M.; Epigenetics in osteoarthritis: Novel spotlight. J Cell Physiol 2019,234(8),12309-12324","journal-title":"J Cell Physiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00011-017-1082-y","volume":"66","author":"Foma A.M.","year":"2017","unstructured":"Foma A.M.; Aslani S.; Karami J.; Jamshidi A.; Mahmoudi M.; Epigenetic involvement in etiopathogenesis and implications in treatment of systemic lupus erythematous. Inflamm Res 2017,66(12),1057-1073","journal-title":"Inflamm Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/imcb.12311","volume":"98","author":"Karami J.","year":"2020","unstructured":"Karami J.; Aslani S.; Tahmasebi M.N.; Mousavi M.J.; Sharafat Vaziri A.; Jamshidi A.; Farhadi E.; Mahmoudi M.; Epigenetics in rheumatoid arthritis; fibroblast-like synoviocytes as an emerging paradigm in the pathogenesis of the disease. Immunol Cell Biol 2020,98(3),171-186","journal-title":"Immunol Cell Biol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1056\/NEJMra1402513","volume":"378","author":"Feinberg A.P.","year":"2018","unstructured":"Feinberg A.P.; The key role of epigenetics in human disease prevention and mitigation. N Engl J Med 2018,378(14),1323-1334","journal-title":"N Engl J Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"102685","DOI":"10.1016\/j.autrev.2020.102685","volume":"19","author":"Pacini G.","year":"2020","unstructured":"Pacini G.; Paolino S.; Andreoli L.; Tincani A.; Gerosa M.; Caporali R.; Iagnocco A.; Ospelt C.; Smith V.; Cutolo M.; Epigenetics, pregnancy and autoimmune rheumatic diseases. Autoimmun Rev 2020,19(12),102685","journal-title":"Autoimmun Rev"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"102777","DOI":"10.1016\/j.autrev.2021.102777","volume":"20","author":"Zouali M.","year":"2021","unstructured":"Zouali M.; B lymphocytes, the gastrointestinal tract and autoimmunity. Autoimmun Rev 2021,20(4),102777","journal-title":"Autoimmun Rev"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"102640","DOI":"10.1016\/j.autrev.2020.102640","volume":"19","author":"Farhat S.C.L.","year":"2020","unstructured":"Farhat S.C.L.; Yariwake V.Y.; Veras M.M.; Braga A.L.F.; Maluf A.E.; Silva C.A.; Inhaled ultrafine particles, epigenetics and systemic autoimmune rheumatic diseases. Autoimmun Rev 2020,19(10),102640","journal-title":"Autoimmun Rev"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-immunol-020711-075013","volume":"30","author":"O\u2019Connell R.M.","year":"2012","unstructured":"O\u2019Connell R.M.; Rao D.S.; Baltimore D.; microRNA regulation of inflammatory responses. Annu Rev Immunol 2012,30(1),295-312","journal-title":"Annu Rev Immunol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrn3234","volume":"13","author":"Qureshi I.A.","year":"2012","unstructured":"Qureshi I.A.; Mehler M.F.; Emerging roles of non-coding RNAs in brain evolution, development, plasticity and disease. Nat Rev Neurosci 2012,13(8),528-541","journal-title":"Nat Rev Neurosci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/exd.12469","volume":"23","author":"Pivarcsi A.","year":"2014","unstructured":"Pivarcsi A.; St\u00e5hle M.; Sonkoly E.; Genetic polymorphisms altering microRNA activity in psoriasis - a key to solve the puzzle of missing heritability? Exp Dermatol 2014,23(9),620-624","journal-title":"Exp Dermatol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"20705","DOI":"10.1073\/pnas.1312237110","volume":"110","author":"Kulkarni S.","year":"2013","unstructured":"Kulkarni S.; Qi Y.; O\u2019hUigin C.; Pereyra F.; Ramsuran V.; McLaren P.; Fellay J.; Nelson G.; Chen H.; Liao W.; Bass S.; Apps R.; Gao X.; Yuki Y.; Lied A.; Ganesan A.; Hunt P.W.; Deeks S.G.; Wolinsky S.; Walker B.D.; Carrington M.; Genetic interplay between HLA-C and MIR148A in HIV control and Crohn disease. Proc Natl Acad Sci USA 2013,110(51),20705-20710","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3109\/08916934.2015.1134511","volume":"49","author":"Aslani S.","year":"2016","unstructured":"Aslani S.; Mahmoudi M.; Karami J.; Jamshidi A.R.; Malekshahi Z.; Nicknam M.H.; Epigenetic alterations underlying autoimmune diseases. Autoimmunity 2016,49(2),69-83","journal-title":"Autoimmunity"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/14397595.2016.1206174","volume":"27","author":"Mahmoudi M.","year":"2017","unstructured":"Mahmoudi M.; Aslani S.; Nicknam M.H.; Karami J.; Jamshidi A.R.; New insights toward the pathogenesis of ankylosing spondylitis; genetic variations and epigenetic modifications. Mod Rheumatol 2017,27(2),198-209","journal-title":"Mod Rheumatol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"14S","DOI":"10.1111\/1523-1747.ep12386079","volume":"102","author":"Krueger G.G.","year":"1994","unstructured":"Krueger G.G.; Duvic M.; Epidemiology of psoriasis: Clinical issues. J Invest Dermatol 1994,102(6),14S-18S","journal-title":"J Invest Dermatol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/1346-8138.13806","volume":"44","author":"Zeng J.","year":"2017","unstructured":"Zeng J.; Luo S.; Huang Y.; Lu Q.; Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol 2017,44(8),863-872","journal-title":"J Dermatol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"12715","DOI":"10.3390\/ijms222312715","volume":"22","author":"Um J.Y.","year":"2021","unstructured":"Um J.Y.; Chung B.Y.; Kim H.B.; Kim J.C.; Park C.W.; Kim H.O.; Aryl hydrocarbon receptor repressor is hypomethylated in psoriasis and promotes psoriasis-like inflammation in HaCaT cells. Int J Mol Sci 2021,22(23),12715","journal-title":"Int J Mol Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13148-018-0541-9","volume":"10","author":"Chandra A.","year":"2018","unstructured":"Chandra A.; Senapati S.; Roy S.; Chatterjee G.; Chatterjee R.; Epigenome-wide DNA methylation regulates cardinal pathological features of psoriasis. Clin Epigenetics 2018,10(1),108","journal-title":"Clin Epigenetics"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jid.2017.11.036","volume":"138","author":"Verma D.","year":"2018","unstructured":"Verma D.; Ekman A.K.; Bivik Eding C.; Enerb\u00e4ck C.; Genome-wide DNA methylation profiling identifies differential methylation in uninvolved psoriatic epidermis. J Invest Dermatol 2018,138(5),1088-1093","journal-title":"J Invest Dermatol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jdermsci.2022.11.001","volume":"108","author":"Deng M.","year":"2022","unstructured":"Deng M.; Su Y.; Wu R.; Li S.; Zhu Y.; Tang G.; Shi X.; Zhou T.; Zhao M.; Lu Q.; DNA methylation markers in peripheral blood for psoriatic arthritis. J Dermatol Sci 2022,108(1),39-47","journal-title":"J Dermatol Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"746145","DOI":"10.3389\/fcell.2021.746145","volume":"9","author":"Charras A.","year":"2021","unstructured":"Charras A.; Garau J.; Hofmann S.R.; Carlsson E.; Cereda C.; Russ S.; Abraham S.; Hedrich C.M.; DNA methylation patterns in CD8 T cells discern psoriasis From psoriatic arthritis and correlate with cutaneous disease activity. Front Cell Dev Biol 2021,9,746145","journal-title":"Front Cell Dev Biol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s11684-017-0588-6","volume":"12","author":"Zhou F.","year":"2018","unstructured":"Zhou F.; Shen C.; Hsu Y.H.; Gao J.; Dou J.; Ko R.; Zheng X.; Sun L.; Cui Y.; Zhang X.; DNA methylation-based subclassification of psoriasis in the Chinese Han population. Front Med 2018,12(6),717-725","journal-title":"Front Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"e0212043","DOI":"10.1371\/journal.pone.0212043","volume":"14","author":"Pollock R.A.","year":"2019","unstructured":"Pollock R.A.; Zaman L.; Chandran V.; Gladman D.D.; Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis. PLoS One 2019,14(2),e0212043","journal-title":"PLoS One"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.2217\/epi-2018-0225","volume":"11","author":"Wu M.","year":"2019","unstructured":"Wu M.; Li X.; Zhang C.; Zhang C.; Qian D.; Ma J.; Cai M.; Tang L.; Cheng H.; Shen C.; Chen G.; Zheng X.; Zhang X.; Zhou F.; DNA methylation profile of psoriatic skins from different body locations. Epigenomics 2019,11(14),1613-1625","journal-title":"Epigenomics"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1517\/17425250902865586","volume":"5","author":"Deb S.","year":"2009","unstructured":"Deb S.; Bandiera S.M.; Characterization and expression of extrahepatic CYP2S1. Expert Opin Drug Metab Toxicol 2009,5(4),367-380","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/S0140-6736(03)13081-4","volume":"361","author":"Smith G.","year":"2003","unstructured":"Smith G.; Wolf C.R.; Deeni Y.Y.; Dawe R.S.; Evans A.T.; Comrie M.M.; Ferguson J.; Ibbotson S.H.; Cutaneous expression of cytochrome P450 CYP2S1: Individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 2003,361(9366),1336-1343","journal-title":"Lancet"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jid.2015.12.029","volume":"136","author":"Zhou F.","year":"2016","unstructured":"Zhou F.; Wang W.; Shen C.; Li H.; Zuo X.; Zheng X.; Yue M.; Zhang C.; Yu L.; Chen M.; Zhu C.; Yin X.; Tang M.; Li Y.; Chen G.; Wang Z.; Liu S.; Zhou Y.; Zhang F.; Zhang W.; Li C.; Yang S.; Sun L.; Zhang X.; Epigenome-wide association analysis identified nine skin DNA methylation loci for psoriasis. J Invest Dermatol 2016,136(4),779-787","journal-title":"J Invest Dermatol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/15592294.2020.1814486","volume":"16","author":"Sheng Y.","year":"2021","unstructured":"Sheng Y.; Wen L.; Zheng X.; Li M.; Wang D.; Chen S.; Li R.; Tang L.; Zhou F.; CYP2S1 might regulate proliferation and immune response of keratinocyte in psoriasis. Epigenetics 2021,16(6),618-628","journal-title":"Epigenetics"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/1523-1747.ep12547129","volume":"71","author":"Krueger G.G.","year":"1978","unstructured":"Krueger G.G.; Hill H.R.; Jederberg W.W.; Inflammatory and immune cell function in psoriasis-a subtle disorder I. in vivo and in vitro survey. J Invest Dermatol 1978,71(3),189-194","journal-title":"J Invest Dermatol"},{"key":"ref=51","first-page":"155","volume":"17","author":"Zarrabeitia M.T.","year":"1989","unstructured":"Zarrabeitia M.T.; Fari\u00f1as M.C.; Rodr\u00edguez-Valverde V.; Riancho J.A.; Llaca H.F.; T and B cell function in psoriasis and psoriatic arthropathy. Allergol Immunopathol (Madr) 1989,17(3),155-159","journal-title":"Allergol Immunopathol (Madr)"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1046\/j.1523-1747.2000.00953.x","volume":"114","author":"Sch\u00f6n M.","year":"2000","unstructured":"Sch\u00f6n M.; Kubitza R.C.; Ruzicka T.; Sch\u00f6n M.P.; Denzer D.; Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice. J Invest Dermatol 2000,114(5),976-983","journal-title":"J Invest Dermatol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1365-2133.2004.05801.x","volume":"150","author":"Rocha-Pereira P.","year":"2004","unstructured":"Rocha-Pereira P.; Santos-Silva A.; Rebelo I.; FigneiRedo A.; Quintanilha A.; Teixeira F.; Erythrocyte damage in mild and severe psoriasis. Br J Dermatol 2004,150(2),232-244","journal-title":"Br J Dermatol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1684\/ejd.2008.0618","volume":"19","author":"Zhang K.","year":"2009","unstructured":"Zhang K.; Zhang R.; Li X.; Yin G.; Niu X.; Promoter methylation status of p15 and p21 genes in HPP-CFCs of bone marrow of patients with psoriasis. Eur J Dermatol 2009,19(2),141-146","journal-title":"Eur J Dermatol"},{"key":"ref=55","first-page":"780","volume":"15","author":"Zhang R.L.","year":"2007","unstructured":"Zhang R.L.; Niu X.P.; Li X.H.; Zhang K.M.; Yin G.H.; CFU-HPP colony formation of bone marrow hematopoietic proginitor cells in psoriatic patients and methylation of p16 gene promotor in CFU-HPP colony cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007,15(4),780-784","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"Griffiths C.E.M.","year":"2007","unstructured":"Griffiths C.E.M.; Barker J.N.W.N.; Pathogenesis and clinical features of psoriasis. Lancet 2007,370(9583),263-271","journal-title":"Lancet"},{"key":"ref=57","first-page":"1321","volume":"151","author":"Wrone-Smith T.","year":"1997","unstructured":"Wrone-Smith T.; Mitra R.S.; Thompson C.B.; Jasty R.; Castle V.P.; Nickoloff B.J.; Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 1997,151(5),1321-1329","journal-title":"Am J Pathol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2133.2008.08505.x","volume":"158","author":"Chen M.","year":"2008","unstructured":"Chen M.; Chen Z-Q.; Cui P-G.; Yao X.; Li Y-M.; Li A-S.; Gong J-Q.; Cao Y-H.; The methylation pattern of p16 gene promoter in psoriatic epidermis and its clinical significance. Br J Dermatol 2008,158(5),987-993","journal-title":"Br J Dermatol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00109-005-0020-6","volume":"84","author":"Ruchusatsawat K.","year":"2006","unstructured":"Ruchusatsawat K.; Wongpiyabovorn J.; Shuangshoti S.; Hirankarn N.; Mutirangura A.; SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis. J Mol Med (Berl) 2006,84(2),175-182","journal-title":"J Mol Med (Berl)"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jdermsci.2016.04.003","volume":"83","author":"Chen M.","year":"2016","unstructured":"Chen M.; Wang Y.; Yao X.; Li C.; Jiang M.; Cui P.; Wang B.; Hypermethylation of HLA-C may be an epigenetic marker in psoriasis. J Dermatol Sci 2016,83(1),10-16","journal-title":"J Dermatol Sci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"12323","DOI":"10.18632\/oncotarget.12468","volume":"8","author":"Zong W.","year":"2017","unstructured":"Zong W.; Ge Y.; Han Y.; Yang X.; Li Q.; Chen M.; Hypomethylation of HLA-DRB1 and its clinical significance in psoriasis. Oncotarget 2017,8(7),12323-12332","journal-title":"Oncotarget"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jdermsci.2020.05.006","volume":"99","author":"Tang L.","year":"2020","unstructured":"Tang L.; Yao T.; Fang M.; Zheng X.; Chen G.; Li M.; Wang D.; Li X.; Ma H.; Wang X.; Qian Y.; Zhou F.; Genomic DNA methylation in HLA-Cw*0602 carriers and non-carriers of psoriasis. J Dermatol Sci 2020,99(1),23-29","journal-title":"J Dermatol Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13148-016-0297-z","volume":"8","author":"Zhou F.","year":"2016","unstructured":"Zhou F.; Shen C.; Xu J.; Gao J.; Zheng X.; Ko R.; Dou J.; Cheng Y.; Zhu C.; Xu S.; Tang X.; Zuo X.; Yin X.; Cui Y.; Sun L.; Tsoi L.C.; Hsu Y.H.; Yang S.; Zhang X.; Epigenome-wide association data implicates DNA methylation-mediated genetic risk in psoriasis. Clin Epigenetics 2016,8(1),131","journal-title":"Clin Epigenetics"},{"key":"ref=64","author":"Ruchusatsawat K.","year":"2016","unstructured":"Ruchusatsawat K.; Thiemsing L.; Mutirangura A.; Wongpiyabovorn J.; BCAP 31 expression and promoter demethylation in psoriasis. Asian Pac J Allergy Immunol 2016","journal-title":"Asian Pac J Allergy Immunol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","volume":"48","author":"Black J.C.","year":"2012","unstructured":"Black J.C.; Van Rechem C.; Whetstine J.R.; Histone lysine methylation dynamics: Establishment, regulation, and biological impact. Mol Cell 2012,48(4),491-507","journal-title":"Mol Cell"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/371832","volume":"2011","author":"Peserico A.","year":"2011","unstructured":"Peserico A.; Simone C.; Physical and functional HAT\/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol 2011,2011,1-10","journal-title":"J Biomed Biotechnol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jdermsci.2021.07.003","volume":"103","author":"Masalha M.","year":"2021","unstructured":"Masalha M.; Ben-Dov I.Z.; Ram O.; Meningher T.; Jacob-Hirsch J.; Kassem R.; Sidi Y.; Avni D.; H3K27Ac modification and gene expression in psoriasis. J Dermatol Sci 2021,103(2),93-100","journal-title":"J Dermatol Sci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"107793","DOI":"10.1016\/j.intimp.2021.107793","volume":"96","author":"Liao Y.","year":"2021","unstructured":"Liao Y.; Su Y.; Wu R.; Zhang P.; Feng C.; Overexpression of Wilms tumor 1 promotes IL-1\u03b2 expression by upregulating histone acetylation in keratinocytes. Int Immunopharmacol 2021,96,107793","journal-title":"Int Immunopharmacol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"699900","DOI":"10.3389\/fimmu.2021.699900","volume":"12","author":"Zeng J.","year":"2021","unstructured":"Zeng J.; Zhang Y.; Zhang H.; Zhang Y.; Gao L.; Tong X.; Xie Y.; Hu Q.; Chen C.; Ding S.; Lu J.; RPL22 overexpression promotes psoriasis-like lesion by inducing keratinocytes abnormal biological behavior. Front Immunol 2021,12,699900","journal-title":"Front Immunol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s41419-020-03028-1","volume":"11","author":"Zhang T.","year":"2020","unstructured":"Zhang T.; Yang L.; Ke Y.; Lei J.; Shen S.; Shao S.; Zhang C.; Zhu Z.; Dang E.; Wang G.; EZH2-dependent epigenetic modulation of histone H3 lysine-27 contributes to psoriasis by promoting keratinocyte proliferation. Cell Death Dis 2020,11(10),826","journal-title":"Cell Death Dis"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/s41467-018-03704-z","volume":"9","author":"Li H.","year":"2018","unstructured":"Li H.; Yao Q.; Mariscal A.G.; Wu X.; H\u00fclse J.; Pedersen E.; Helin K.; Waisman A.; Vinkel C.; Thomsen S.F.; Avgustinova A.; Benitah S.A.; Lovato P.; Norsgaard H.; Mortensen M.S.; Veng L.; Rozell B.; Brakebusch C.; Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation. Nat Commun 2018,9(1),1420","journal-title":"Nat Commun"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1172\/JCI129269","volume":"130","author":"Xia X.","year":"2020","unstructured":"Xia X.; Cao G.; Sun G.; Zhu L.; Tian Y.; Song Y.; Guo C.; Wang X.; Zhong J.; Zhou W.; Li P.; Zhang H.; Hao J.; Li Z.; Deng L.; Yin Z.; Gao Y.; GLS1-mediated glutaminolysis unbridled by MALT1 protease promotes psoriasis pathogenesis. J Clin Invest 2020,130(10),5180-5196","journal-title":"J Clin Invest"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1684\/ejd.2011.1383","volume":"21","author":"Zhang P.","year":"2011","unstructured":"Zhang P.; Su Y.; Zhao M.; Huang W.; Lu Q.; Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris. Eur J Dermatol 2011,21(4),552-557","journal-title":"Eur J Dermatol"},{"key":"ref=74","first-page":"111","volume":"13","author":"Trowbridge R.M.","year":"2014","unstructured":"Trowbridge R.M.; Pittelkow M.R.; Epigenetics in the pathogenesis and pathophysiology of psoriasis vulgaris. J Drugs Dermatol 2014,13(2),111-118","journal-title":"J Drugs Dermatol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/exd.13790","volume":"27","author":"Ovejero-Benito M.C.","year":"2018","unstructured":"Ovejero-Benito M.C.; Reolid A.; S\u00e1nchez-Jim\u00e9nez P.; Saiz-Rodr\u00edguez M.; Mu\u00f1oz-Aceituno E.; Llamas-Velasco M.; Mart\u00edn-Vilchez S.; Cabaleiro T.; Rom\u00e1n M.; Ochoa D.; Daud\u00e9n E.; Abad-Santos F.; Histone modifications associated with biological drug response in moderate-to-severe psoriasis. Exp Dermatol 2018,27(12),1361-1371","journal-title":"Exp Dermatol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/jid.2008.179","volume":"129","author":"Blander G.","year":"2009","unstructured":"Blander G.; Bhimavarapu A.; Mammone T.; Maes D.; Elliston K.; Reich C.; Matsui M.S.; Guarente L.; Loureiro J.J.; SIRT1 promotes differentiation of normal human keratinocytes. J Invest Dermatol 2009,129(1),41-49","journal-title":"J Invest Dermatol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/life10090157","volume":"10","author":"Hwang Y.J.","year":"2020","unstructured":"Hwang Y.J.; Na J.I.; Byun S.Y.; Kwon S.H.; Yang S.H.; Lee H.S.; Choi H.R.; Cho S.; Youn S.W.; Park K.C.; Histone deacetylase 1 and sirtuin 1 expression in psoriatic skin: A comparison between guttate and plaque psoriasis. Life (Basel) 2020,10(9),157","journal-title":"Life (Basel)"},{"key":"ref=78","first-page":"83","volume":"3","author":"Shukla G.C.","year":"2011","unstructured":"Shukla G.C.; Singh J.; Barik S.; MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol 2011,3(3),83-92","journal-title":"Mol Cell Pharmacol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/ni.f.209","volume":"9","author":"Baltimore D.","year":"2008","unstructured":"Baltimore D.; Boldin M.P.; O\u2019Connell R.M.; Rao D.S.; Taganov K.D.; MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008,9(8),839-845","journal-title":"Nat Immunol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000493952","volume":"50","author":"Qiao M.","year":"2018","unstructured":"Qiao M.; Ding J.; Yan J.; Li R.; Jiao J.; Sun Q.; Circular RNA expression profile and analysis of their potential function in psoriasis. Cell Physiol Biochem 2018,50(1),15-27","journal-title":"Cell Physiol Biochem"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1684\/ejd.2018.3483","volume":"29","author":"Liu R.","year":"2019","unstructured":"Liu R.; Wang Q.; Chang W.; Zhou L.; Li J.; Zhang K.; Characterisation of the circular RNA landscape in mesenchymal stem cells from psoriatic skin lesions. Eur J Dermatol 2019,29(1),29-38","journal-title":"Eur J Dermatol"},{"key":"ref=82","author":"Haschka J.","year":"2023","unstructured":"Haschka J.; Simon D.; Bayat S.; Messner Z.; Kampylafka E.; Fagni F.; Skalicky S.; Hackl M.; Resch H.; Zwerina J.; Kleyer A.; Cavallaro A.; Sticherling M.; Schett G.; Kocijan R.; Rech J.; Identification of circulating microRNA patterns in patients in psoriasis and psoriatic arthritis. Rheumatology 2023","journal-title":"Rheumatology"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"14186","DOI":"10.1038\/s41598-021-93616-8","volume":"11","author":"Soonthornchai W.","year":"2021","unstructured":"Soonthornchai W.; Tangtanatakul P.; Meesilpavikkai K.; Dalm V.; Kueanjinda P.; Wongpiyabovorn J.; MicroRNA-378a-3p is overexpressed in psoriasis and modulates cell cycle arrest in keratinocytes via targeting BMP2 gene. Sci Rep 2021,11(1),14186","journal-title":"Sci Rep"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1371\/journal.pone.0000610","volume":"2","author":"Sonkoly E.","year":"2007","unstructured":"Sonkoly E.; Wei T.; Janson P.C.J.; S\u00e4f A.; Lundeberg L.; Tengvall-Linder M.; Norstedt G.; Alenius H.; Homey B.; Scheynius A.; St\u00e5hle M.; Pivarcsi A.; MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One 2007,2(7),e610","journal-title":"PLoS One"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.cyto.2012.07.031","volume":"60","author":"Primo M.N.","year":"2012","unstructured":"Primo M.N.; Bak R.O.; Schibler B.; Mikkelsen J.G.; Regulation of pro-inflammatory cytokines TNF\u03b1 and IL24 by microRNA-203 in primary keratinocytes. Cytokine 2012,60(3),741-748","journal-title":"Cytokine"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"988962","DOI":"10.3389\/fmed.2022.988962","volume":"9","author":"Mostafa S.A.","year":"2022","unstructured":"Mostafa S.A.; Mohammad M.H.S.; Negm W.A.; Batiha G.E.S.; Alotaibi S.S.; Albogami S.M.; Waard M.D.; Tawfik N.Z.; Abdallah H.Y.; Circulating microRNA203 and its target genes\u2019 role in psoriasis pathogenesis. Front Med (Lausanne) 2022,9,988962","journal-title":"Front Med (Lausanne)"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40291-021-00531-9","volume":"25","author":"Leal B.","year":"2021","unstructured":"Leal B.; Carvalho C.; Ferreira A.M.; Nogueira M.; Br\u00e1s S.; Silva B.M.; Selores M.; Costa P.P.; Torres T.; Serum levels of miR-146a in patients with psoriasis. Mol Diagn Ther 2021,25(4),475-485","journal-title":"Mol Diagn Ther"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"e24198","DOI":"10.1002\/jcla.24198","volume":"36","author":"Shen H.","year":"2022","unstructured":"Shen H.; Wang D.; Zhan M.; Ding H.; Zhao H.; MicroRNA-146a and microRNA-146b deficiency correlates with exacerbated disease activity, and their longitude increment relates to etanercept response in psoriasis patients. J Clin Lab Anal 2022,36(2),e24198","journal-title":"J Clin Lab Anal"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/cdd.2008.69","volume":"15","author":"Lena A.M.","year":"2008","unstructured":"Lena A.M.; Shalom-Feuerstein R.; di Val Cervo P.R.; Aberdam D.; Knight R.A.; Melino G.; Candi E.; miR-203 represses \u2018stemness\u2019 by repressing \u0394Np63. Cell Death Differ 2008,15(7),1187-1195","journal-title":"Cell Death Differ"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jdermsci.2010.03.004","volume":"58","author":"Zibert J.R.","year":"2010","unstructured":"Zibert J.R.; L\u00f8vendorf M.B.; Litman T.; Olsen J.; Kaczkowski B.; Skov L.; MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci 2010,58(3),177-185","journal-title":"J Dermatol Sci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1159\/000515114","volume":"34","author":"Meng Z.","year":"2021","unstructured":"Meng Z.; Qiu J.; Zhang H.; MiR-221-3p as a potential bfor Patients with psoriasis and its role in inflammatory responses in keratinocytes. Skin Pharmacol Physiol 2021,34(5),300-306","journal-title":"Skin Pharmacol Physiol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/jid.2011.55","volume":"131","author":"Xu N.","year":"2011","unstructured":"Xu N.; Brodin P.; Wei T.; Meisgen F.; Eidsmo L.; Nagy N.; Kemeny L.; St\u00e5hle M.; Sonkoly E.; Pivarcsi A.; MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2. J Invest Dermatol 2011,131(7),1521-1529","journal-title":"J Invest Dermatol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1159\/000510681","volume":"237","author":"Su F.","year":"2021","unstructured":"Su F.; Jin L.; Liu W.; MicroRNA-125acorrelates with decreased psoriasis severity and inflammation and represses keratinocyte proliferation. Dermatology 2021,237(4),568-578","journal-title":"Dermatology"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1093\/hmg\/ddr331","volume":"20","author":"Joyce C.E.","year":"2011","unstructured":"Joyce C.E.; Zhou X.; Xia J.; Ryan C.; Thrash B.; Menter A.; Zhang W.; Bowcock A.M.; Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet 2011,20(20),4025-4040","journal-title":"Hum Mol Genet"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1600-0625.2012.01462.x","volume":"21","author":"Meisgen F.","year":"2012","unstructured":"Meisgen F.; Xu N.; Wei T.; Janson P.C.; Obad S.; Broom O.; Nagy N.; Kauppinen S.; Kem\u00e9ny L.; St\u00e5hle M.; Pivarcsi A.; Sonkoly E.; MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp Dermatol 2012,21(4),312-314","journal-title":"Exp Dermatol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"678","DOI":"10.4049\/jimmunol.1202695","volume":"190","author":"Xu N.","year":"2013","unstructured":"Xu N.; Meisgen F.; Butler L.M.; Han G.; Wang X.J.; S\u00f6derberg-Naucl\u00e9r C.; St\u00e5hle M.; Pivarcsi A.; Sonkoly E.; MicroRNA-31 is overexpressed in psoriasis and modulates inflammatory cytokine and chemokine production in keratinocytes via targeting serine\/threonine kinase 40. J Immunol 2013,190(2),678-688","journal-title":"J Immunol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3892\/etm.2021.10176","volume":"22","author":"Ye Y.","year":"2021","unstructured":"Ye Y.; Wang P.; Zhou F.; miR-489-3p inhibits TLR4\/NF-\u03baB signaling to prevent inflammation in psoriasis. Exp Ther Med 2021,22(1),744","journal-title":"Exp Ther Med"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e20916","DOI":"10.1371\/journal.pone.0020916","volume":"6","author":"Lerman G.","year":"2011","unstructured":"Lerman G.; Avivi C.; Mardoukh C.; Barzilai A.; Tessone A.; Gradus B.; Pavlotsky F.; Barshack I.; Polak-Charcon S.; Orenstein A.; Hornstein E.; Sidi Y.; Avni D.; MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R. PLoS One 2011,6(6),e20916","journal-title":"PLoS One"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/jid.2013.427","volume":"134","author":"Choi H.R.","year":"2014","unstructured":"Choi H.R.; Nam K.M.; Park S.J.; Kim D.S.; Huh C.H.; Park W.Y.; Park K.C.; Suppression of miR135b increases the proliferative potential of normal human keratinocytes. J Invest Dermatol 2014,134(4),1161-1164","journal-title":"J Invest Dermatol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/j.1365-2133.2011.10497.x","volume":"165","author":"Ichihara A.","year":"2011","unstructured":"Ichihara A.; Jinnin M.; Yamane K.; Fujisawa A.; Sakai K.; Masuguchi S.; Fukushima S.; Maruo K.; Ihn H.; microRNA-mediated keratinocyte hyperproliferation in psoriasis vulgaris. Br J Dermatol 2011,165(5),1003-1010","journal-title":"Br J Dermatol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1684\/ejd.2011.1600","volume":"22","author":"Ichihara A.","year":"2012","unstructured":"Ichihara A.; Jinnin M.; Oyama R.; Yamane K.; Fujisawa A.; Sakai K.; Masuguchi S.; Fukushima S.; Maruo K.; Ihn H.; Increased serum levels of miR-1266 in patients with psoriasis vulgaris. Eur J Dermatol 2012,22(1),68-71","journal-title":"Eur J Dermatol"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.4049\/jimmunol.1800189","volume":"201","author":"Bian J.","year":"2018","unstructured":"Bian J.; Liu R.; Fan T.; Liao L.; Wang S.; Geng W.; Wang T.; Shi W.; Ruan Q.; miR-340 alleviates psoriasis in mice through direct targeting of IL-17A. J Immunology 2018,201(5),1412-1420","journal-title":"J Immunology"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clim.2013.10.009","volume":"150","author":"Zhao M.","year":"2014","unstructured":"Zhao M.; Wang L.; Liang G.; Zhang P.; Deng X.; Tang Q.; Zhai H.; Chang C.C.; Su Y.; Lu Q.; Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4+ T cells of psoriasis vulgaris. Clin Immunol 2014,150(1),22-30","journal-title":"Clin Immunol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1172\/JCI97426","volume":"128","author":"Wu R.","year":"2018","unstructured":"Wu R.; Zeng J.; Yuan J.; Deng X.; Huang Y.; Chen L.; Zhang P.; Feng H.; Liu Z.; Wang Z.; Gao X.; Wu H.; Wang H.; Su Y.; Zhao M.; Lu Q.; MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation. J Clin Invest 2018,128(6),2551-2568","journal-title":"J Clin Invest"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/j.jid.2017.06.005","volume":"137","author":"Jiang M.","year":"2017","unstructured":"Jiang M.; Sun Z.; Dang E.; Li B.; Fang H.; Li J.; Gao L.; Zhang K.; Wang G.; TGF\u03b2\/SMAD\/microRNA-486-3p signaling axis mediates keratin 17 expression and keratinocyte hyperproliferation in psoriasis. J Invest Dermatol 2017,137(10),2177-2186","journal-title":"J Invest Dermatol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41419-018-0621-y","volume":"9","author":"Zhang W.","year":"2018","unstructured":"Zhang W.; Yi X.; An Y.; Guo S.; Li S.; Song P.; Chang Y.; Zhang S.; Gao T.; Wang G.; Li C.; MicroRNA-17-92 cluster promotes the proliferation and the chemokine production of keratinocytes: Implication for the pathogenesis of psoriasis. Cell Death Dis 2018,9(5),567","journal-title":"Cell Death Dis"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4081\/ejh.2022.3275","volume":"66","author":"Li Q.","year":"2022","unstructured":"Li Q.; Zhang J.; Liu S.; Zhang F.; Zhuang J.; Chen Y.; MicroRNA-17-3p is upregulated in psoriasis and regulates keratinocyte hyperproliferation and pro-inflammatory cytokine secretion by targeting CTR9. Eur J Histochem 2022,66(1),66","journal-title":"Eur J Histochem"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/6264474","volume":"2022","author":"Liu S.","year":"2022","unstructured":"Liu S.; Gong J.; miR-124-3p delivered using exosomes attenuates the keratinocyte response to IL-17A stimulation in psoriasis. Oxid Med Cell Longev 2022,2022,1-11","journal-title":"Oxid Med Cell Longev"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bjd.17256","volume":"180","author":"Yan J.J.","year":"2019","unstructured":"Yan J.J.; Qiao M.; Li R.H.; Zhao X.T.; Wang X.Y.; Sun Q.; Downregulation of miR-145-5p contributes to hyperproliferation of keratinocytes and skin inflammation in psoriasis. Br J Dermatol 2019,180(2),365-372","journal-title":"Br J Dermatol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.biopha.2017.05.005","volume":"91","author":"Shen H.","year":"2017","unstructured":"Shen H.; Zeng B.; Wang C.; Tang X.; Wang H.; Liu W.; Yang Z.; MiR-330 inhibits IL-22-induced keratinocyte proliferation through targeting CTNNB1. Biomed Pharmacother 2017,91,803-811","journal-title":"Biomed Pharmacother"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"51288","DOI":"10.18632\/oncotarget.17260","volume":"8","author":"Zheng Y.Z.","year":"2017","unstructured":"Zheng Y.Z.; Chen C.F.; Jia L.Y.; Yu T.G.; Sun J.; Wang X.Y.; Correlation between microRNA-143 in peripheral blood mononuclear cells and disease severity in patients with psoriasis vulgaris. Oncotarget 2017,8(31),51288-51295","journal-title":"Oncotarget"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.biopha.2017.03.105","volume":"90","author":"Xu L.","year":"2017","unstructured":"Xu L.; Leng H.; Shi X.; Ji J.; Fu J.; Leng H.; MiR-155 promotes cell proliferation and inhibits apoptosis by PTEN signaling pathway in the psoriasis. Biomed Pharmacother 2017,90,524-530","journal-title":"Biomed Pharmacother"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jdermsci.2014.01.005","volume":"74","author":"Koga Y.","year":"2014","unstructured":"Koga Y.; Jinnin M.; Ichihara A.; Fujisawa A.; Moriya C.; Sakai K.; Fukushima S.; Inoue Y.; Ihn H.; Analysis of expression pattern of serum microRNA levels in patients with psoriasis. J Dermatol Sci 2014,74(2),170-171","journal-title":"J Dermatol Sci"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/jid.2011.139","volume":"131","author":"Jorn Bovenschen H.","year":"2011","unstructured":"Jorn Bovenschen H.; van de Kerkhof P.C.; van Erp P.E.; Woestenenk R.; Joosten I.; Koenen H.J.P.M.; Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 2011,131(9),1853-1860","journal-title":"J Invest Dermatol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"10768","DOI":"10.1073\/pnas.1501956112","volume":"112","author":"Hammitzsch A.","year":"2015","unstructured":"Hammitzsch A.; Tallant C.; Fedorov O.; O\u2019Mahony A.; Brennan P.E.; Hay D.A.; Martinez F.O.; Al-Mossawi M.H.; de Wit J.; Vecellio M.; Wells C.; Wordsworth P.; M\u00fcller S.; Knapp S.; Bowness P.; CBP30, a selective CBP\/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci USA 2015,112(34),10768-10773","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/exd.14502","volume":"31","author":"Samuelov L.","year":"2022","unstructured":"Samuelov L.; Bochner R.; Magal L.; Malovitski K.; Sagiv N.; Nousbeck J.; Keren A.; Fuchs-Telem D.; Sarig O.; Gilhar A.; Sprecher E.; Vorinostat, a histone deacetylase inhibitor, as a potential novel treatment for psoriasis. Exp Dermatol 2022,31(4),567-576","journal-title":"Exp Dermatol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"e24307","DOI":"10.1371\/journal.pone.0024307","volume":"6","author":"Orecchia A.","year":"2011","unstructured":"Orecchia A.; Scarponi C.; Di Felice F.; Cesarini E.; Avitabile S.; Mai A.; Mauro M.L.; Sirri V.; Zambruno G.; Albanesi C.; Camilloni G.; Failla C.M.; Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. PLoS One 2011,6(9),e24307","journal-title":"PLoS One"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41419-019-2212-y","volume":"11","author":"Thatikonda S.","year":"2020","unstructured":"Thatikonda S.; Pooladanda V.; Sigalapalli D.K.; Godugu C.; Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation. Cell Death Dis 2020,11(1),21","journal-title":"Cell Death Dis"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/1346-8138.15149","volume":"47","author":"Feng H.","year":"2020","unstructured":"Feng H.; Wu R.; Zhang S.; Kong Y.; Liu Z.; Wu H.; Wang H.; Su Y.; Zhao M.; Lu Q.; Topical administration of nanocarrier miRNA-210 antisense ameliorates imiquimod-induced psoriasis-like dermatitis in mice. J Dermatol 2020,47(2),147-154","journal-title":"J Dermatol"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.2174\/1381612823666170601105439","volume":"23","author":"Rajitha P.","year":"2017","unstructured":"Rajitha P.; Biswas R.; Sabitha M.; Jayakumar R.; Methotrexate in the treatment of psoriasis and rheumatoid arthritis: mechanistic insights, current issues and novel delivery approaches. Curr Pharm Des 2017,23(24),3550-3566","journal-title":"Curr Pharm Des"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230503143824","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/216482\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230503143824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T19:12:09Z","timestamp":1729365129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/216482\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":120,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666230503143824","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}